LXE408 + sodium stibogluconate + Paromomycin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Visceral Leishmaniasis
Conditions
Primary Visceral Leishmaniasis
Trial Timeline
Mar 29, 2024 → Nov 13, 2025
NCT ID
NCT05957978About LXE408 + sodium stibogluconate + Paromomycin
LXE408 + sodium stibogluconate + Paromomycin is a phase 2 stage product being developed by Novartis for Primary Visceral Leishmaniasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05957978. Target conditions include Primary Visceral Leishmaniasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05957978 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Visceral Leishmaniasis